• Tommaso Maria Manzia, Carlo Gazia, Ilaria Lenci, Roberta Angelico, Luca Toti, Andrea Monaco, Alessandro Anselmo, Leonardo Baiocchi, Paolo Grossi, and Giuseppe Tisone.
• Hepato-Pancreato-Biliary and Transplant Unit, University of Rome Tor Vergata, Rome, Italy.
• Am. J. Transplant. 2021 Jul 1; 21 (7): 2600-2604.

AbstractThe coronavirus disease 2019 (COVID-19) is a novel infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). COVID-19 currently affected more than 108 million people worldwide with a fatality rate of 2.2%. Herein, we report the first case of liver transplantation (LT) performed with a liver procured from a SARS-CoV-2 positive donor. The recipient was a 35-year-old SARS-CoV-2 positive female patient affected by severe end-stage HBV-HDV-related liver disease (model of end-stage liver disease = 32) who had neutralizing SARS-CoV-2 antibodies (titers 1:320) at time of LT. The LT was successful, and the graft is functioning two months after surgery. The recipient cleared the SARS-CoV-2 infection 1 month after LT. The current case shows that the prompt use of SARS-CoV-2 infected liver donors offers an invaluable life-saving opportunity for SARS-CoV-2 positive wait-listed patients who developed neutralizing SARS-CoV-2 antibodies.© 2021 The American Society of Transplantation and the American Society of Transplant Surgeons.

15 keywords...

hide…